PL358267A1 - Kompozycja do zapobiegania i/lub leczenia efektówcytotoksycznych powodowanych stosowaniem środków immunosupresyjnych - Google Patents

Kompozycja do zapobiegania i/lub leczenia efektówcytotoksycznych powodowanych stosowaniem środków immunosupresyjnych

Info

Publication number
PL358267A1
PL358267A1 PL01358267A PL35826701A PL358267A1 PL 358267 A1 PL358267 A1 PL 358267A1 PL 01358267 A PL01358267 A PL 01358267A PL 35826701 A PL35826701 A PL 35826701A PL 358267 A1 PL358267 A1 PL 358267A1
Authority
PL
Poland
Prior art keywords
prevention
treatment
composition
immunosuppressive agents
cytotoxic effects
Prior art date
Application number
PL01358267A
Other languages
English (en)
Other versions
PL202682B1 (pl
Inventor
Claudio Cavazza
Original Assignee
Sigma-Tau Healthscience S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Healthscience S.P.A. filed Critical Sigma-Tau Healthscience S.P.A.
Publication of PL358267A1 publication Critical patent/PL358267A1/pl
Publication of PL202682B1 publication Critical patent/PL202682B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL358267A 2000-03-02 2001-02-20 Kompozycja do zapobiegania i/lub leczenia zmian komórkowych i tkankowych i jej zastosowanie PL202682B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2000RM000107A IT1316998B1 (it) 2000-03-02 2000-03-02 Composizione per la prevenzione e/o il trattamento degli effetticitotossici indotti dall'uso di agenti immunosoppressori.
PCT/IT2001/000082 WO2001064204A2 (en) 2000-03-02 2001-02-20 Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents

Publications (2)

Publication Number Publication Date
PL358267A1 true PL358267A1 (pl) 2004-08-09
PL202682B1 PL202682B1 (pl) 2009-07-31

Family

ID=11454493

Family Applications (1)

Application Number Title Priority Date Filing Date
PL358267A PL202682B1 (pl) 2000-03-02 2001-02-20 Kompozycja do zapobiegania i/lub leczenia zmian komórkowych i tkankowych i jej zastosowanie

Country Status (19)

Country Link
US (1) US7897641B2 (pl)
EP (1) EP1267863B1 (pl)
AR (1) AR027963A1 (pl)
AT (1) ATE335476T1 (pl)
AU (2) AU2001241031B8 (pl)
CA (1) CA2400728C (pl)
CY (1) CY1106169T1 (pl)
CZ (1) CZ20022759A3 (pl)
DE (1) DE60122120T2 (pl)
DK (1) DK1267863T3 (pl)
ES (1) ES2269356T3 (pl)
HU (1) HUP0300083A3 (pl)
IT (1) IT1316998B1 (pl)
MX (1) MXPA02008531A (pl)
PL (1) PL202682B1 (pl)
PT (1) PT1267863E (pl)
SK (1) SK11892002A3 (pl)
TN (1) TNSN01032A1 (pl)
WO (1) WO2001064204A2 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6775419B2 (ja) * 2014-04-22 2020-10-28 味の素株式会社 末梢神経障害の予防又は改善用組成物
CN115469026B (zh) * 2022-07-14 2023-10-20 中日友好医院(中日友好临床医学研究所) 用于检测环孢素a肾毒性相关标志物的检测试剂、试剂盒及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1120033B (it) * 1979-10-05 1986-03-19 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale
US5290538A (en) * 1988-12-22 1994-03-01 Skrezek Christian Nephro protective infusion solutions
JPH0662547B2 (ja) * 1989-01-10 1994-08-17 田辺製薬株式会社 グリシン誘導体
IT1248323B (it) * 1991-05-16 1995-01-05 Sigma Tau Ind Farmaceuti Ammidi con amminoacidi naturali di alcanoil l-carnitine quali inibitori della degenerazione neuronale e attivatori dei processi di apprendimento e memorizzazione e per il trattamento del coma e composizioni farmaceutiche comprendenti tali composti
IT1245869B (it) 1991-06-05 1994-10-25 Sigma Tau Ind Farmaceuti Impiego di propionil l-carnitina per il recupero del tono muscolare in soggetti immobilizzati
US5763408A (en) * 1992-06-03 1998-06-09 Fuji Photo Film Co., Ltd. Amino acid derivatives and application thereof
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
IT1277147B1 (it) * 1995-01-20 1997-11-04 Sigma Tau Ind Farmaceuti Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi.
EP0793962B1 (en) * 1996-03-04 1999-12-08 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Medicament containing a carnitine derivative for treating arteriosclerosis obliterans
US6348495B1 (en) * 1996-06-06 2002-02-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Method for treating celiac disease
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
US5922766A (en) * 1997-07-02 1999-07-13 Acosta; Phyllis J. B. Palatable elemental medical food
IT1302863B1 (it) 1998-11-13 2000-10-10 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante e preventiva di alterazionitrombotiche e aterosclerotiche comprendente una carnitina ed un
IT1306130B1 (it) * 1999-04-16 2001-05-30 Sigma Tau Healthscience Spa Composizione comprendente una carnitina e glutatione, atta adaumentare l'assorbimento del glutatione sinergizzandone gli effetti.
IT1306173B1 (it) * 1999-07-23 2001-05-30 Sigma Tau Healthscience Spa Composizione per la prevenzione degli affaticamenti muscolari e permigliorare il rendimento energetico muscolare.
IT1306722B1 (it) * 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di
IT1307278B1 (it) * 1999-11-18 2001-10-30 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disturbi dovutiad un alterato metabolismo dei lipidi, che comprende propionil
IT1317062B1 (it) * 2000-07-14 2003-05-26 Sigma Tau Healthscience Spa Integratore alimentare utile per prevenire le disfunzioni epatiche ebiliari comprendente una alcanoil l-carnitina.
ITRM20010155A1 (it) * 2001-03-23 2002-09-23 Biosalts Srl Sale di creatina ad aumentato valore nutrizionale e terapeutico e composizioni che lo contengono.

Also Published As

Publication number Publication date
WO2001064204A2 (en) 2001-09-07
ATE335476T1 (de) 2006-09-15
CY1106169T1 (el) 2011-06-08
AU2001241031B8 (en) 2005-12-01
DE60122120T2 (de) 2007-02-08
EP1267863B1 (en) 2006-08-09
TNSN01032A1 (fr) 2005-11-10
MXPA02008531A (es) 2003-02-12
PL202682B1 (pl) 2009-07-31
AU4103101A (en) 2001-09-12
ITRM20000107A0 (it) 2000-03-02
DE60122120D1 (de) 2006-09-21
US20030144354A1 (en) 2003-07-31
IT1316998B1 (it) 2003-05-26
CA2400728C (en) 2009-04-28
HUP0300083A3 (en) 2004-07-28
AU2001241031B2 (en) 2005-10-27
US7897641B2 (en) 2011-03-01
WO2001064204A3 (en) 2002-03-28
PT1267863E (pt) 2006-10-31
SK11892002A3 (sk) 2003-02-04
DK1267863T3 (da) 2006-12-04
ES2269356T3 (es) 2007-04-01
ITRM20000107A1 (it) 2001-09-02
CA2400728A1 (en) 2001-09-07
CZ20022759A3 (cs) 2003-02-12
HUP0300083A2 (hu) 2003-06-28
EP1267863A2 (en) 2003-01-02
AR027963A1 (es) 2003-04-16

Similar Documents

Publication Publication Date Title
HUP0201409A2 (en) Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria
HUP0103920A3 (en) Methods and compositions for the prevention and treatment of anemia
AU8870701A (en) Materials and methods for the treatment or prevention of obesity
AU6147401A (en) Compositions and methods for the treatment of cancer
IL158181A0 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
IL196301A0 (en) Medicament for the treatment of hapatitis c
AU2877202A (en) Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
IL130424A (en) Compositions comprising ziprasidone or its hydrochloride monohydrate, their preparation and use thereof in the preparation of medicaments for treating psychosis
TW200626526A (en) Pharmaceutical compositions for the treatment of neoplasms
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
HUP0303566A3 (en) Pharmaceutical composition containing combination of fenofibrate and coenzyme q10 and its use for the treatment of endothelial dysfunction
HUP0104688A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
HUP0003410A3 (en) A pharmaceutical compositions containing azapolycylic compounds for the prevention and treatment of nicotine addition in a mammal
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
HUP0302738A3 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
AU2001264522A1 (en) Methods and compositions for the prevention of myopia
HUP0300083A3 (en) Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents
IL147410A0 (en) L-acetylcarnitine and l-propionylcarnitine containing composition for the prevention and treatment of kidney dysfunctions and diseases
AU8906201A (en) Methods and compositions for the treatment and prevention of sexual dysfunction
GB9802542D0 (en) New use
HUP0002154A3 (en) Use of famotidine for the preparation of pharmaceutical compositions treating depression or symptoms related with depression
EP1305017A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF SYNDROME X
GB9904252D0 (en) Composition for the treatment of pain